In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Managing the Onslaught of Biotech Injectables

Executive Summary

The steady stream of new biologics is putting increasing pressure on both payers and manufacturers to re-evaluate long-standing ways of doing business. The average retail pharmacy--or PBM for that matter--isn't equipped to deal with complexities related to these drugs and hence the need for SPPs--special pharmaceutical providers. SPPs have started up in abundance in recent years to handle therapeutics with difficult administrative regimens and high costs. Biotech companies are using them in a variety of ways.

You may also be interested in...

Henry Schein's Bid to Move Up the Pharma Value Chain

Henry Schein, the dental and medical supplies distributor, is known for its strong relationship with physicians' offices, where it is a major supplier of med-surge products, equipment, pharma injectables and vaccines. Now it wants to fill in gaps that pharma companies aren't paying attention to--and in the process move up the value chain. It is expanding into specialty pharmacy, and seeking to strike deals with vaccine makers. It also has set up a small business development operation to look for in-licensing opportunities.

Launching Avastin

Genentech Inc.'s launched three major drugs in nine months, two in therapeutic areas new to it and the third in a new drug class. The latter, Avastin, is an oncology drug which stifles growth of tumors by cutting off their blood supply. Sales have exceeded expectations.The very high cost isn't likely deter use--even as payers scrutinize oncology costs more seriously--because of the solid trial data and political sensitivities inherent in rationing drugs for terminally ill patients.

As Specialty Pharmacy Evolves, Biotech Companies Stay Tuned

As biotech products ripen, manufacturers facing the prospect of launching complex, expensive drugs are turning to specialty pharmacy providers for help. A new breed of business, they provide clinical and logistical support. The recent entry of PBMs into the specialty pharmacy arena, along with new Medicare rules, is likely to accelerate pricing pressure on manufacturers and affect their relationships with distributors, payers, and providers.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts